Greenwich LifeSciences Stock Gains on GP2 Update (GLSI)


Update the digital concept

Olemedia

Greenwich LifeSciences (NASDAQ:GLSI) rose on Wednesday after the immunotherapy developer updated on the commercial manufacture of its lead GP2 candidate, which is currently undergoing a late-stage trial called FLAMINGO-01 for breast cancer.

Given that commercial manufacturing data as well



Source link

  • Related Posts

    EU plans subsidy for EV car sales to counter China

    Stay informed with free updates Just sign up to Electric vehicles myFT Digest — delivered directly to your inbox. Brussels has promised to help the European car industry as much…

    Medtronic hires CFO from Renault

    Medtronic hires CFO from Renault Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *